Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25777215 | 1.00 | GPR119 (0.42) | GPR119CYP19A1CYP17A1MAPK1KDM5A | |
| SCHEMBL25912217 | 1.00 | GPR119 (0.42) | GPR119CYP19A1CYP17A1MAPK1KDM5A | |
| SCHEMBL25797633 | 1.00 | GPR119 (0.42) | GPR119CYP19A1CYP17A1MAPK1KDM5A | |
| SCHEMBL25777220 | 1.00 | GPR119 (0.42) | GPR119CYP19A1CYP17A1MAPK1KDM5A | |
| SCHEMBL25777214 | 1.00 | GPR119 (0.42) | GPR119CYP19A1CYP17A1MAPK1KDM5A | |
| SCHEMBL25797631 | 0.86 | GPR119 (0.34) | GPR119 | |
| SCHEMBL25912216 | 0.86 | GPR119 (0.34) | GPR119 | |
| SCHEMBL25912218 | 0.86 | GPR119 (0.34) | GPR119 | |
| SCHEMBL31536544 | 0.82 | GPR119 (0.41) | GPR119 | |
| SCHEMBL31536590 | 0.82 | GPR119 (0.41) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| CN-116457358-A | Indole derivatives as RAS inhibitors for the treatment of cancer | 锐新医药公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | GPR119 3465/4885CYP19A1 4395/4885CYP17A1 4637/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | GPR119 3465/4885CYP19A1 4395/4885CYP17A1 4637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.